Free Trial
→ 2013 Bitcoin miner reveals his trading system (free) (From Crypto Swap Profits) (Ad)tc pixel Free TAK Stock Alerts

Takeda Pharmaceutical (TAK) Stock Forecast & Price Target

Takeda Pharmaceutical logo
$15.10 -0.03 (-0.17%)
As of 03:54 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Compare

Takeda Pharmaceutical - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Hold
Based on 2 Analyst Ratings
Sell
1
Hold
0
Buy
1

Based on 2 Wall Street analysts who have issued ratings for Takeda Pharmaceutical in the last 12 months, the stock has a consensus rating of "Hold." Out of the 2 analysts, 1 has given a sell rating, and 1 has given a buy rating for TAK.

Consensus Price Target

N/A

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for TAK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Takeda Pharmaceutical and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TAK Analyst Ratings Over Time

TypeCurrent Forecast
9/17/24 to 9/17/25		1 Month Ago
8/18/24 to 8/18/25		3 Months Ago
6/19/24 to 6/19/25		1 Year Ago
9/18/23 to 9/17/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
 N/A
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
 N/A
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
 N/A
Sell
1 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
 N/A
Consensus Price TargetN/AN/AN/AN/A
Forecasted UpsideN/AN/AN/AN/A
Consensus RatingHoldBuyBuyN/A

TAK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TAK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Takeda Pharmaceutical Stock vs. The Competition

TypeTakeda PharmaceuticalMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.78
2.53
Consensus RatingHoldModerate BuyModerate Buy
Predicted UpsideN/A17,153.07% Upside11.49% Upside
News Sentiment Rating
Neutral News

See Recent TAK News
Positive News
Positive News
Export to Excel
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside		Details
8/21/2025Zacks Research
0 of 5 stars		 DowngradeHold ➝ Strong Sell
4/2/2025Morgan Stanley
3 of 5 stars		 UpgradeEqual Weight ➝ Overweight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 03:54 PM ET.


Should I Buy Takeda Pharmaceutical Stock? TAK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, September 16, 2025. Please send any questions or comments about these Takeda Pharmaceutical pros and cons to contact@marketbeat.com.

Takeda Pharmaceutical
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Takeda Pharmaceutical Company Limited:

  • The current stock price is around $15.59, which reflects a recent increase, indicating positive market sentiment towards the company.
  • Takeda Pharmaceutical Company Limited recently reached a new 52-week high, suggesting strong performance and investor confidence.
  • The company reported earnings per share (EPS) of $0.52, exceeding analysts' expectations, which may indicate effective management and operational efficiency.
  • Institutional investors have shown increased interest, with significant stakes being added, which often signals confidence in the company's future prospects.
  • Takeda has a solid market capitalization of approximately $48 billion, providing a stable foundation for growth and investment opportunities.

Takeda Pharmaceutical
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Takeda Pharmaceutical Company Limited for these reasons:

  • Zacks Research downgraded the stock from a "hold" rating to a "strong sell," which may indicate potential concerns about the company's future performance.
  • The company has a relatively high P/E ratio, suggesting that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • Recent quarterly revenue fell short of analysts' expectations, which could raise concerns about the company's growth trajectory.
  • Takeda's net margin is relatively low, indicating that the company may not be as profitable as some of its competitors, which could affect long-term sustainability.
  • The stock has shown volatility, with fluctuations in trading volume, which may pose risks for investors seeking stable returns.

TAK Forecast - Frequently Asked Questions

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last twelve months. There is currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" TAK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TAK, but not buy additional shares or sell existing shares.

According to analysts, Takeda Pharmaceutical's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.

Over the previous 90 days, Takeda Pharmaceutical's stock had 1 downgrade by analysts.

Takeda Pharmaceutical has been rated by research analysts at Zacks Research in the past 90 days.

Analysts like Takeda Pharmaceutical less than other "medical" companies. The consensus rating for Takeda Pharmaceutical is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how TAK compares to other companies.

Related Companies
Today's Ratings
Top-Rated Stocks
More Ratings Tools

This page (NYSE:TAK) was last updated on 9/17/2025 by MarketBeat.com Staff
From Our Partners
He Called Nvidia at $1.10. Now, He Says THIS Stock Will…
The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...
The Oxford Club | Sponsoredtc pixel
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel
Trump’s Plan May Undo 1933’s Biggest Financial Injustice
Trump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...
American Hartford Gold | Sponsoredtc pixel
Strange crypto pattern discovered by 40-person research team
Something unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...
Crypto Swap Profits | Sponsoredtc pixel
Why Trump’s “Smart Dollar” could rewrite the rules
MUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...
Stansberry Research | Sponsoredtc pixel
Trump's Law S.1582: $21T Dollar Revolution Coming
Do you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...
Brownstone Research | Sponsoredtc pixel
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank ac...
Weiss Ratings | Sponsoredtc pixel
Forget AI Stocks — This Device Will REPLACE the Microchip
While everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...
Banyan Hill Publishing | Sponsoredtc pixel